| Title |
Cardiometabolic Effects of Anti-obesity Pharmacotherapy
|
|---|---|
| Published in |
Current Atherosclerosis Reports, March 2018
|
| DOI | 10.1007/s11883-018-0719-9 |
| Pubmed ID | |
| Authors |
Andrew R. Crawford, Naji Alamuddin, Anastassia Amaro |
| Abstract |
We review recent studies discussing the impact of pharmacologic agents for weight loss on clinical cardiovascular events, as well as cardiometabolic risk factors. Pharmacotherapy with current FDA-approved medications for weight loss can significantly improve known risk factors for the development of cardiovascular disease such as hypertension, hyperlipidemia, insulin resistance, inflammatory biomarkers, and the quantity of visceral fat, as well as non-alcoholic fatty liver disease. However, data regarding the actual reduction in clinical cardiovascular events with the use of weight loss medications is scarce. Pharmacotherapy for weight loss may have additional benefit in optimizing patient's cardiometabolic comorbidities and improving their clinical cardiovascular outcomes, but each drug should be carefully selected based upon individual patient characteristics. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 15% |
| Student > Bachelor | 5 | 13% |
| Researcher | 4 | 10% |
| Student > Doctoral Student | 3 | 8% |
| Other | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 14 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 36% |
| Nursing and Health Professions | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Unspecified | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 15 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2018.
All research outputs
#20,468,008
of 23,026,672 outputs
Outputs from Current Atherosclerosis Reports
#714
of 768 outputs
Outputs of similar age
#293,401
of 331,979 outputs
Outputs of similar age from Current Atherosclerosis Reports
#14
of 16 outputs
Altmetric has tracked 23,026,672 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 768 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,979 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.